Streetbeat News

Products Services

VIR

Vir Biotechnology's shares have dropped following the failure of its Phase 2 PENINSULA trial of VIR-2482, aimed at preventing symptomatic influenza A illness, to meet primary or secondary efficacy endpoints.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 12:46 pm

CMCSA

Nielsen has renewed a multi-year data license agreement with Comcast Corporation. The agreement will allow Nielsen to expand its use of Comcast's return path data (RPD) in its national and local television and cross-media measurement services. The inclusion of RPD from Comcast expands Nielsen's current big data footprint to nearly 45 million households. The expansion of Nielsen's measurement using Comcast RPD will be introduced into the market in 2024.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 12:37 pm

SGHT

Sight Sciences has announced that its Sahara clinical trial, which compared interventional eyelid procedures enabled by TearCare technology to Restasis for the treatment of dry eye, has met its primary endpoint. The company's stock symbol is SGHT.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 12:36 pm

AMPX

Amprius Technologies (NYSE:AMPX) announced that its high-density batteries powered BAE Systems' first successful stratospheric flight trial. The trial allowed engineers to assess the experimental solar-electric drone within the edges of the planet's atmosphere. Amprius entered into a three-year cooperation agreement with BAE Systems in October 2022 to investigate business opportunities enabled by the use and supply of Amprius' silicon anode batteries for electric products being developed by BAE Systems in the UK.

Portfolio Pulse from Happy Mohamed

July 20, 2023 | 12:34 pm

VS

Versus Systems Inc. (NASDAQ:VS) has announced a strategic partnership with game creator Maestro Media. The partnership aims to expand Versus' product portfolio and support Maestro Media's upcoming gaming campaigns. Versus' digital marketing platform will leverage existing Maestro Media campaigns and products to enhance brand and consumer experiences. The partnership will also allow players to earn in-game prizes related to Maestro Media games and merchandise.

Portfolio Pulse from Happy Mohamed

July 20, 2023 | 12:33 pm

TTOO

T2 Biosystems has received FDA Breakthrough Device Designation for its Candida Auris diagnostic test. This designation will expedite the development and review process of the test.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 12:31 pm

PFE

Pfizer Inc has announced promising data from a Phase 2 study of its GBS6 vaccine candidate, developed to protect infants against invasive Group B Streptococcus (GBS) disease. The study enrolled 360 healthy pregnant individuals in South Africa, and the vaccine generated robust maternal antibody responses. The data suggests that GBS6 may offer meaningful protection against invasive GBS disease in newborns and young infants. Pfizer's shares are up 0.22% at $36.52 during the premarket session on the last check Thursday.

Portfolio Pulse from Vandana Singh

July 20, 2023 | 12:27 pm

PETV

PetVivo Holdings, Inc. (NASDAQ:PETV) has achieved national distribution of its product, Spryng with OsteoCushion, to over 450 veterinary clinics across 47 states. The company is nearing a milestone of supplying its product to its 500th clinic. The product, an intra-articular injectable veterinary medical device, is used in the management of lameness and other joint related afflictions in animals.

Portfolio Pulse from Happy Mohamed

July 20, 2023 | 12:24 pm

GH

Guardant Health, Inc. (NASDAQ:GH) announced that Blue Cross and Blue Shield of Louisiana will now cover its Guardant Reveal molecular residual disease (MRD) test. The test, which detects circulating tumor DNA in blood after treatment, will be covered for individuals with stage II or III colorectal cancer after curative treatment. The coverage is effective from July 10 and is aligned with monitoring guidelines established by the National Comprehensive Cancer Network for colorectal cancer.

Portfolio Pulse from Happy Mohamed

July 20, 2023 | 12:21 pm

AAPL

Apple Inc.'s (NASDAQ:AAPL) iPhone 15 launch could be delayed to October, according to a Bank of America analyst. This could impact Apple's sales in the September quarter and push it back to the December quarter. The prediction is based on supply chain checks. The iPhone 15 series is expected to launch in September alongside the Apple Watch Series 9 and Apple Watch Ultra 2.

Portfolio Pulse from Rounak Jain

July 20, 2023 | 12:20 pm